• The last patient included in the study completed the last follow-up visit planned by the protocol.
• The first results of the study will be communicated before the end of the first half of 2023, after the freezing of the database and the statistical analysis work.
• This international and multicentre Phase II/III study evaluates the efficacy of TOTUM•63, an active substance of plant origin, in a population with impaired glucose metabolism, from prediabetes to untreated type 2 diabetes (early stage ).
• Its main objective is the reduction of fasting glycaemia after 24 weeks of supplementation with a daily dose of 5 g of TOTUM•63, in 3 daily doses, compared to the placebo.
• The REVERSE-IT study was co-designed by Nestlé Health Science and Valbiotis, as part of the global strategic partnership between the two companies on TOTUM•63; as such, the results of the study are associated with milestone payments from Nestlé Health Science.